Medication info
Empagliflozin 25 mg Tablet

Empagliflozin 25 mg Tablet

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP × 3)]
Approval status
Active

MFDS item code 202105848 · Approved 2021.08.11 · Insurance code 643508880

Summary

Main use
Improves glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 10 mg once daily, as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions for Use, 4. General Precautions).

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes

View approved original text

This medication is used in conjunction with dietary and exercise management to help control blood sugar in adult patients with Type 2 diabetes. It can be administered alone or in combination with other medications. Patients with insufficient blood sugar control and cardiovascular disease need to be particularly cautious about the occurrence of cardiovascular events, so please refer to the precautions for use. Therefore, this medication is used effectively to control blood sugar in patients with Type 2 diabetes.

How to take

Adult dose

The recommended dose of this medicine is 10 mg once daily, as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions for Use, 4. General Precautions).

Precautions

This medication should not be used in patients with an allergic reaction to the active ingredient or any of its components. It should not be administered to patients with Type 1 diabetes or diabetic ketoacidosis. Patients with severely impaired renal function, end-stage renal disease, or those undergoing dialysis should not use this medication. Since this medication contains lactose, patients with lactose intolerance, galactose intolerance, or hereditary lactose intolerance should not take it. Patients with some degree of impaired renal function should use this medication cautiously, and dose adjustments or discontinuation may be necessary based on renal function status. In cases of severe heart failure, the use of this medication is not recommended, so caution is advised. When combined with insulin or insulin secretagogues, there may be a risk of hypoglycemia, which may require dose adjustment. While taking this medication, side effects such as hypoglycemia, genital infections, increased urination, urinary tract infections, and fluid depletion may occur, so symptoms should be closely monitored. Particularly, serious metabolic diseases such as ketoacidosis may occur; if symptoms arise, immediate consultation with healthcare professionals is required. Elderly patients or those at high risk of fluid volume loss should be cautious of dehydration and hypotension, and if necessary, the administration of this medication may be temporarily suspended. This medication may affect kidney function, so regular renal function monitoring is recommended. There is a risk of serious urinary tract infections such as urosepsis and pyelonephritis; if infection symptoms appear, prompt treatment is necessary. Use of this medication during pregnancy is not recommended, and it should be discontinued if pregnancy is confirmed. In breastfeeding patients, this medication may be excreted in breast milk, so it is safer to halt breastfeeding. Its safety and efficacy have not been established in children under 18 years of age, so it is not used in this population. No specific toxic symptoms have been reported in cases of overdose; however, appropriate treatment is required depending on the patient's condition. This medication should be kept out of reach of children and should not be transferred to other containers. When driving or operating machinery, particularly when used with insulin or sulfonylureas, caution against the risk of hypoglycemia is advised. Rare serious side effects such as limb amputation or perineal necrosis have been reported, so if relevant symptoms occur, immediate notification to healthcare professionals is necessary.

Side effects

  • Hypoglycemia
  • ketoacidosis
  • vulvovaginitis
  • balanitis
  • other genital infections
  • urinary tract infections
  • perineal necrosis
  • pruritus
  • rash
  • urticaria
Show 18 more
  • angioedema
  • decreased fluid volume
  • increased urination
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased blood creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urosepsis
  • pyelonephritis
  • decreased blood pressure
  • dehydration
  • hypotension
  • decreased blood volume
  • orthostatic hypotension
  • syncope

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. The recommended storage temperature is room temperature between 1 degree and 30 degrees.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP × 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.